Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials

Nature Communications

Volumn 7, Issue , 2016, Pages

  Morvan, Claire ^a,h   Halpern, David ^a   Kénanian, Gérald ^a   Hays, Constantin ^b,c,d   Anba Mondoloni, Jamila ^a   Brinster, Sophie ^b,c,i   Kennedy, Sean ^e,f   Trieu Cuot, Patrick ^f,g   Poyart, Claire ^b,c,d   Lamberet, Gilles ^a   Gloux, Karine ^a   Gruss, Alexandra ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT COCHIN   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔTEL DIEU   (France)

^e UMR1319 MICALIS   (France)

^f INSTITUT PASTEUR   (France)

^g CNRS   (France)

^h INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

ⁱ Society Lubro   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFN 1252; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; FABD PROTEIN; FATTY ACID; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE II; FATTY ACID SYNTHASE INHIBITOR; PLATENSIMYCIN; TRICLOSAN; UNCLASSIFIED DRUG; ACYL CARRIER PROTEIN MALONYLTRANSFERASE; ANTIINFECTIVE AGENT; ESCHERICHIA COLI PROTEIN; FABD PROTEIN, E COLI;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; ENZYME; FATTY ACID; GROWTH; INHIBITION; INHIBITOR; MUTATION; RODENT; VIRULENCE;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; CROSS RESISTANCE; DNA POLYMORPHISM; DRUG DESIGN; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE TARGETING; HOST PATHOGEN INTERACTION; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTATION RATE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; UBIQUITINATION; ALLELE; ANIMAL; BAGG ALBINO MOUSE; DNA SEQUENCE; DRUG EFFECT; FEMALE; GENETIC COMPLEMENTATION; GENETIC POLYMORPHISM; LIPOGENESIS; METABOLISM; MOLECULAR CLONING; MUTATION; VIRULENCE;

BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ACYL-CARRIER PROTEIN S-MALONYLTRANSFERASE; ALLELES; ANIMALS; ANTI-BACTERIAL AGENTS; CLONING, MOLECULAR; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI PROTEINS; FATTY ACID SYNTHASE, TYPE II; FATTY ACIDS; FEMALE; GENETIC COMPLEMENTATION TEST; LIPOGENESIS; MICE; MICE, INBRED BALB C; MUTATION; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS AUREUS; TRICLOSAN; VIRULENCE;

EID: 84990909249     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12944     Document Type: Article

References (67)

1. Lowy, F. D. Methicillin-resistant Staphylococcus aureus: where is it coming from and where is it going? JAMA Internal Med. 173, 1978-1979 (2013).
2. Uhlemann, A. C., Otto, M., Lowy, F. D. & DeLeo, F. R. Evolution of community-and healthcare-associated methicillin-resistant Staphylococcus aureus. Infect. Genet. Evol. 21, 563-574 (2014).
3. Banevicius, M. A., Kaplan, N., Hafkin, B. & Nicolau, D. P. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J. Chemother. 25, 26-31 (2013).
4. Escaich, S. et al. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob. Agents Chemother. 55, 4692-4697 (2011).
5. Feng, Z., Chakraborty, D., Dewell, S. B., Reddy, B. V. & Brady, S.F. Environmental DNA-encoded antibiotics fasamycins A and B inhibit FabF in type II fatty acid biosynthesis. J. Am. Chem. Soc. 134, 2981-2987 (2012).
6. Moir, D. T., Opperman, T. J., Butler, M. M. & Bowlin, T. L. New classes of antibiotics. Curr. Opin. Pharmacol. 12, 535-544 (2012).
7. Park, H. S. et al. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J. Antimicrob. Chemother. 60, 568-574 (2007).
8. Park, H. S. et al. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Int. J. Antimicrob. Agents 30, 446-451 (2007).
9. Schiebel, J. et al. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. J. Biol. Chem. 289, 15987-16005 (2014).
10. Wang, J. et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl Acad. Sci. USA 104, 7612-7616 (2007).
11. Wang, J. et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358-361 (2006).
12. McMurry, L. M., Oethinger, M. & Levy, S. B. Triclosan targets lipid synthesis. Nature 394, 531-532 (1998).
13. Webster, J., Faoagali, J. L. & Cartwright, D. Elimination of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit after hand washing with triclosan. J. Paediatr. Child Health 30, 59-64 (1994).
14. Bamber, A. I. & Neal, T. J. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J. Hosp. Infect. 41, 107-109 (1999).
15. Bhargava, H. N. & Leonard, P. A. Triclosan: applications and safety. Am. J. Infect. Control 24, 209-218 (1996).
16. Brenwald, N. P. & Fraise, A. P. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J. Hosp. Infect. 55, 141-144 (2003).
17. Cherednichenko, G. et al. Triclosan impairs excitation-contraction coupling and Ca2+ dynamics in striated muscle. Proc. Natl Acad. Sci. USA 109, 14158-14163 (2012).
18. Syed, A. K., Ghosh, S., Love, N. G. & Boles, B. R. Triclosan promotes Staphylococcus aureus nasal colonization. MBio 5, e01015 (2014).
19. Yueh, M. F. et al.The commonly used antimicrobial additive triclosan is a liver tumor promoter. Proc. Natl Acad. Sci. USA (2014).
20. Ciusa, M. L. et al. A novel resistance mechanism to triclosan that suggests horizontal gene transfer and demonstrates a potential selective pressure for reduced biocide susceptibility in clinical strains of Staphylococcus aureus. Int. J. Antimicrob. Agents 40, 210-220 (2012).
21. Balemans, W. et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463, E3-E4 (2010).
22. Kaplan, N., Garner, C. & Hafkin, B. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Eur. J. Pharm. Sci. 50, 440-446 (2013).
23. Parsons, J. B. & Rock, C. O. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol. 14, 544-549 (2011).
24. Schiebel, J. et al. Staphylococcus aureus FabI: inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20, 802-813 (2012).
25. Brinster, S. et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458, 83-86 (2009).
26. Brinster, S. et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463, E4-E5 (2010).
27. Parsons, J. B., Frank, M.W., Subramanian, C., Saenkham, P. & Rock, C.O. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. USA 108, 15378-15383 (2011).
28. Zhu, L. et al. The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance. MBio 4, e00613-e00613 (2013).
29. Kaplan, N. et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob. Agents Chemother. 56, 5865-5874 (2012).
30. Parsons, J. B. et al. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob. Agents Chemother. 57, 2182-2190 (2013).
31. Parsons, J. B. et al. Identification of a two-component fatty acid kinase responsible for host fatty acid incorporation by Staphylococcus aureus. Proc. Natl Acad. Sci. USA 111, 10532-10537 (2014).
32. Parsons, J. B., Frank, M. W., Rosch, J. W. & Rock, C. O. Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob. Agents Chemother. 57, 5729-5732 (2013).
33. Coleman, J. Characterization of the Escherichia coli gene for 1-acyl-sn-glycerol-3-phosphate acyltransferase (plsC). Mol. Gen. Genet. 232, 295-303 (1992).
34. Parsons, J. B., Yao, J., Jackson, P., Frank, M. & Rock, C. O. Phosphatidylglycerol homeostasis in glycerol-phosphate auxotrophs of Staphylococcus aureus. BMC Microbiol. 13, 260 (2013).
35. Nakamura, T. et al. Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study. Br. J. Nutr. 89, 267-272 (2003).
36. Ni Raghallaigh, S., Bender, K., Lacey, N., Brennan, L. & Powell, F. C. The fatty acid profile of the skin surface lipid layer in papulopustular rosacea. Br. J. Dermatol. 166, 279-287 (2012).
37. Greenway, D. L. & Dyke, K. G. Mechanism of the inhibitory action of linoleic acid on the growth of Staphylococcus aureus. J. Gen. Microbiol. 115, 233-245 (1979).
38. Parsons, J. B., Yao, J., Frank, M. W., Jackson, P. & Rock, C. O. Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus. J. Bacteriol. 194, 5294-5304 (2012).
39. Schluepen, C. et al. Mining the bacterial unknown proteome: identification and characterization of a novel family of highly conserved protective antigens in Staphylococcus aureus. Biochem. J. 455, 273-284 (2013).
40. Krishnamurthy, M., Tadesse, S., Rothmaier, K. & Graumann, P. L. A novel SMC-like protein, SbcE (YhaN), is involved in DNA double-strand break repair and competence in Bacillus subtilis. Nucleic Acids Res. 38, 455-466 (2010).
41. Hong, S. K. et al. New design platform for malonyl-CoA-acyl carrier protein transacylase. FEBS Lett. 584, 1240-1244 (2010).
42. Serre, L., Verbree, E. C., Dauter, Z., Stuitje, A. R. & Derewenda, Z. S. The Escherichia coli malonyl-CoA:acyl carrier protein transacylase at 1.5-A resolution. Crystal structure of a fatty acid synthase component. J. Biol. Chem. 270, 12961-12964 (1995).
43. Parsons, J. B., Frank, M. W., Jackson, P., Subramanian, C. & Rock, C. O. Incorporation of extracellular fatty acids by a fatty acid kinase-dependent pathway in Staphylococcus aureus. Mol. Microbiol. 92, 234-245 (2014).
44. Hafkin, B., Kaplan, N. & Murphy, B. Efficacy and safety of AFN-1252, the first staphylococcus-specific antibacterial agent, in the treatment of ABSSSI, including patients with significant co-morbidities. Antimicrob. Agents Chemother. 60, 1695-1701 (2015).
45. Chen, C. J. et al. Characterization and comparison of 2 distinct epidemic community-associated methicillin-resistant Staphylococcus aureus clones of ST59 lineage. PLoS One 8, e63210 (2013).
46. Cronan, J. E. & Thomas, J. Bacterial fatty acid synthesis and its relationships with polyketide synthetic pathways. Methods Enzymol. 459, 395-433 (2009).
47. Masoudi, A., Raetz, C. R., Zhou, P. & Pemble, C. W. T. Chasing acyl carrier protein through a catalytic cycle of lipid A production. Nature 505, 422-426 (2014).
48. Kaplan, N. et al. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J. Chemother. 25, 18-25 (2013).
49. Yum, J. H. et al. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob. Agents Chemother. 51, 2591-2593 (2007).
50. Ruch, F. E. & Vagelos, P. R. The isolation and general properties of Escherichia coli malonyl coenzyme A-acyl carrier protein transacylase. J. Biol. Chem. 248, 8086-8094 (1973).
51. Albanesi, D. et al. Structural basis for feed-forward transcriptional regulation of membrane lipid homeostasis in Staphylococcus aureus. PLoS Pathog. 9, e1003108 (2013).
52. Schujman, G. E., Paoletti, L., Grossman, A. D. & de Mendoza, D. FapR, a bacterial transcription factor involved in global regulation of membrane lipid biosynthesis. Dev. Cell 4, 663-672 (2003).
53. Martinez, M. A. et al. A novel role of malonyl-ACP in lipid homeostasis. Biochemistry 49, 3161-3167 (2010).
54. Do, T. Q. et al. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid. J. Immunol. 181, 4177-4187 (2008).
55. Lin, Y. T. et al. Emergence of a small colony variant of vancomycinintermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin. J. Antimicrob. Chemother. 71, 1807-1814 (2016).
56. Kubota, N. et al. First isolation of oleate-dependent Enterococcus faecalis smallcolony variants from the umbilical exudate of a paediatric patient with omphalitis. J. Med. Microbiol. 62, 1883-1890 (2013).
57. Nicolaides, N. Skin lipids: their biochemical uniqueness. Science 186, 19-26 (1974).
58. Becker, L. C. et al. Final report of the amended safety assessment of myristic acid and its salts and esters as used in cosmetics. Int. J. Toxicol. 29, 162S-186S (2010).
59. Fitzgerald, J. R. Evolution of Staphylococcus aureus during human colonization and infection. Infect. Genet. Evol. 21, 542-547 (2014).
60. Herbert, S. et al. Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect. Immun. 78, 2877-2889 (2010).
61. Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. Science 277, 1453-1462 (1997).
62. Yamamoto, Y. et al. The Group B Streptococcus NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence. Mol. Microbiol. 62, 772-785 (2006).
63. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343-345 (2009).
64. Lartigue, M. F. & Bouloc, P. A tetracycline-inducible expression vector for Streptococcus agalactiae allowing controllable gene expression. J. Microbiol. Methods 96, 16-18 (2014).
65. Kraemer, G. R. & Iandolo, J. J. High-frequency transformation of Staphylococcus aureus by electroporation. Curr. Microbiol. 21, 373-376 (1990)
66. Post-Beittenmiller, D., Jaworski, J. G. & Ohlrogge, J. B. In vivo pools of free and acylated acyl carrier proteins in spinach. Evidence for sites of regulation of fatty acid biosynthesis. J. Biol. Chem. 266, 1858-1865 (1991).
67. Zhang, Y. M. & Rock, C. O. Membrane lipid homeostasis in bacteria. Nat. Rev. Microbiol. 6, 222-233 (2008).